Race-Related Differences in Sipuleucel-T Response Among Men with Metastatic Castrate-Resistant Prostate Cancer

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Jun 10

PMID 38856749

Authors

Elisabeth I Heath

Archana Thakur

Wei Chen

Clara Hwang

Channing J Paller

Frank C Cackowski

Julie L Boerner

Lance Heilbrun

Melanie P Smith

Dana L Schalk

Amy Schienschang

Sarah A Whitaker

Amanda Polend

Daryn Smith

Ulka N Vaishampayan

Brenda Dickow

Lawrence G Lum

Affiliations

Soon will be listed here.

Abstract

Significance: Our novel findings of higher expression of co-stimulatory receptor ICOS on CD4+ and CD8+ T cells in African American patients with metastatic castrate-resistant prostate cancer (mCRPC) prior and post-sipuleucel-T suggest activation of CD4+ and CD8+ T cells. The data indicate that racial differences observed in these and other immune correlates before and after sipuleucel-T warrant additional investigation to further our understanding of the immune system in African American men and other men with mCRPC.

Citing Articles

Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T.

Brown M, DAnniballe V, Boczkowski D, Kandadi H, Sheikh N, Kornahrens Jr W Cancer Res Commun. 2024; 4(10):2724-2733.

PMID: 39320053 PMC: 11487532. DOI: 10.1158/2767-9764.CRC-24-0439.

References

Wei X, Chan S, Kwek S, Lewis J, Dao V, Zhang L . Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016; 4(11):948-958. PMC: 5115633. DOI: 10.1158/2326-6066.CIR-16-0042. View

Sentana-Lledo D, Sartor O, Balk S, Einstein D . Immune mechanisms behind prostate cancer in men of African ancestry: A review. Prostate. 2022; 82(8):883-893. PMC: 9875381. DOI: 10.1002/pros.24333. View

Antonarakis E, Subudhi S, Pieczonka C, Karsh L, Quinn D, Hafron J . Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clin Cancer Res. 2023; 29(13):2426-2434. PMC: 10320463. DOI: 10.1158/1078-0432.CCR-22-3832. View

Ning Z, Liu K, Xiong H . Roles of BTLA in Immunity and Immune Disorders. Front Immunol. 2021; 12:654960. PMC: 8043046. DOI: 10.3389/fimmu.2021.654960. View

Sartor O, Armstrong A, Ahaghotu C, McLeod D, Cooperberg M, Penson D . Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 2020; 23(3):517-526. PMC: 7423504. DOI: 10.1038/s41391-020-0213-7. View

Mantovani A, Dinarello C, Molgora M, Garlanda C . Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity. 2019; 50(4):778-795. PMC: 7174020. DOI: 10.1016/j.immuni.2019.03.012. View

Fuertes M, Kacha A, Kline J, Woo S, Kranz D, Murphy K . Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011; 208(10):2005-16. PMC: 3182064. DOI: 10.1084/jem.20101159. View

Esteves A, Papaevangelou E, Smolarek D, Dasgupta P, Galustian C . Cytotopic (Cyto-) IL-15 as a New Immunotherapy for Prostate Cancer: Recombinant Production in and Purification. Front Mol Biosci. 2021; 8:755764. PMC: 8578882. DOI: 10.3389/fmolb.2021.755764. View

Laheurte C, Thiery-Vuillemin A, Calcagno F, Legros A, Simonin H, Boullerot L . Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer. Int J Cancer. 2019; 147(4):1199-1205. DOI: 10.1002/ijc.32803. View

10.

Cackowski F, Mahal B, Heath E, Carthon B . Evolution of Disparities in Prostate Cancer Treatment: Is This a New Normal?. Am Soc Clin Oncol Educ Book. 2021; 41:1-12. DOI: 10.1200/EDBK_321195. View

11.

Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher M . Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer. Oncoimmunology. 2019; 8(3):1551651. PMC: 6350690. DOI: 10.1080/2162402X.2018.1551651. View

12.

Turkiewicz A, Luta G, Hughes H, Ranstam J . Statistical mistakes and how to avoid them - lessons learned from the reproducibility crisis. Osteoarthritis Cartilage. 2018; 26(11):1409-1411. DOI: 10.1016/j.joca.2018.07.017. View

13.

Kantoff P, Higano C, Shore N, Berger E, Small E, Penson D . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5):411-22. DOI: 10.1056/NEJMoa1001294. View

14.

Cheever M, Higano C . PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011; 17(11):3520-6. DOI: 10.1158/1078-0432.CCR-10-3126. View

15.

Ahaghotu C, Tyler R, Sartor O . African American Participation in Oncology Clinical Trials--Focus on Prostate Cancer: Implications, Barriers, and Potential Solutions. Clin Genitourin Cancer. 2016; 14(2):105-16. DOI: 10.1016/j.clgc.2015.12.003. View

16.

GuhaThakurta D, Sheikh N, Fan L, Kandadi H, Meagher T, Hall S . Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res. 2015; 21(16):3619-30. PMC: 4868054. DOI: 10.1158/1078-0432.CCR-14-2334. View

17.

Thakur A, Rathore R, Kondadasula S, Uberti J, Ratanatharathorn V, Lum L . Immune T cells can transfer and boost anti-breast cancer immunity. Oncoimmunology. 2018; 7(12):e1500672. PMC: 6279339. DOI: 10.1080/2162402X.2018.1500672. View

18.

Sheikh N, Jones L . CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother. 2008; 57(9):1381-90. PMC: 11030627. DOI: 10.1007/s00262-008-0474-9. View

19.

Antonarakis E, Small E, Petrylak D, Quinn D, Kibel A, Chang N . Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clin Cancer Res. 2018; 24(19):4662-4671. PMC: 6481607. DOI: 10.1158/1078-0432.CCR-18-0638. View

20.

Hawley J, Pan S, Kandadi H, Chaimowitz M, Sheikh N, Drake C . Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T. J Natl Cancer Inst. 2021; 114(2):314-317. PMC: 8826456. DOI: 10.1093/jnci/djab145. View